SQZ Biotechnologies (NYSE:SQZ – Get Rating) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,610,000 shares, a decline of 15.7% from the May 15th total of 1,910,000 shares. Based on an average daily trading volume, of 492,900 shares, the short-interest ratio is presently 3.3 days. Approximately 7.9% of the company’s stock are short sold.
In related news, Director Klavs F. Jensen purchased 14,326 shares of SQZ Biotechnologies stock in a transaction on Wednesday, May 25th. The stock was bought at an average price of $3.52 per share, with a total value of $50,427.52. Following the completion of the transaction, the director now directly owns 353,309 shares of the company’s stock, valued at $1,243,647.68. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 18.00% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Sandy Cove Advisors LLC bought a new position in shares of SQZ Biotechnologies during the fourth quarter worth $462,000. Metropolitan Life Insurance Co NY bought a new position in shares of SQZ Biotechnologies in the 3rd quarter valued at about $104,000. NanoDimension Inc. bought a new position in shares of SQZ Biotechnologies in the 4th quarter valued at about $12,906,000. BlackRock Inc. grew its position in shares of SQZ Biotechnologies by 2.8% in the 3rd quarter. BlackRock Inc. now owns 1,250,090 shares of the company’s stock valued at $18,025,000 after acquiring an additional 34,139 shares during the period. Finally, Bangor Savings Bank bought a new position in shares of SQZ Biotechnologies in the 4th quarter valued at about $99,000. 66.56% of the stock is currently owned by institutional investors.
SQZ Biotechnologies (NYSE:SQZ – Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%. Analysts predict that SQZ Biotechnologies will post -2.87 earnings per share for the current year.
Separately, Chardan Capital assumed coverage on SQZ Biotechnologies in a research note on Wednesday, May 25th. They set a “buy” rating and a $17.00 price target on the stock.
SQZ Biotechnologies Company Profile (Get Rating)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
- Get a free copy of the StockNews.com research report on SQZ Biotechnologies (SQZ)
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- Dividend Stocks and Your Roth IRA
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.